<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-162622</identifier>
<setSpec>0365-6691</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Hypotensive eyedrops: The neverending story. Should we consider more than active principles?</dc:title>
<dc:description xml:lang="en">No disponible</dc:description>
<dc:creator>Zanón-Moreno, V</dc:creator>
<dc:creator>García-Medina, JJ</dc:creator>
<dc:creator>Sanz-González, SM</dc:creator>
<dc:creator>Herrero Vanrell, R</dc:creator>
<dc:creator>Benitez del Castillo Sánchez, J</dc:creator>
<dc:creator>Pinazo-Durán, MD</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">No disponible</dc:description>
<dc:source>Arch Soc Esp Oftalmol;92(5): 199-201, mayo 2017.</dc:source>
<dc:identifier>ibc-162622</dc:identifier>
<dc:title xml:lang="es">Colirios hipotensores: la historia interminable. ¿Hay que considerar algo más que los principios activos?</dc:title>
<dc:subject>^d29633</dc:subject>
<dc:subject>^d28204^s22057</dc:subject>
<dc:subject>^d23106</dc:subject>
<dc:subject>^d28053^s22057</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d962^s22078</dc:subject>
<dc:subject>^d10063^s22073</dc:subject>
<dc:subject>^d11015^s22078</dc:subject>
<dc:type>article</dc:type>
<dc:date>201705</dc:date>
</metadata>
</record>
</ibecs-document>
